Phosphoproteome Profiling Revealed the Importance of mTOR Inhibition on CDK1 Activation to Further Regulate Cell

Luqi Jin1, Yu Chen1, Chunlan Yan2

  • 1Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China.

Insights

mTOR inhibition by rapamycin activates CDK1, a key cell cycle regulator. This activation, mediated by the Greatwall-endosulfine complex, further influences cell cycle progression, revealing a novel regulatory pathway.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • The mammalian target of rapamycin (mTOR) is a crucial regulator of cell cycle progression.
  • The precise mechanisms by which mTOR controls the cell cycle are not fully understood.

Purpose of the Study:

  • To elucidate the downstream molecular events and signaling pathways regulated by mTOR inhibition.
  • To identify key kinases and protein complexes involved in mTOR-mediated cell cycle control.

Main Methods:

  • Global phosphoproteome analysis using stable isotope labeling and quantitative mass spectrometry.
  • Inhibition of mTOR signaling using rapamycin.
  • Kinase inhibitor treatments for pathway interrogation.

Main Results:

  • Rapamycin treatment led to the downregulation of the mTOR signaling pathway.
  • Elevated levels of cell cycle-related phosphosites and activation of CDK1, MAPK1, and MAPK3 were observed.
  • CDK1 activation was confirmed to function downstream of mTOR inhibition and was linked to the Greatwall-endosulfine complex.

Conclusions:

  • A comprehensive phosphoproteome map of mTOR inhibition by rapamycin was generated.
  • mTOR inhibition promotes CDK1 activation, which further regulates cell cycle progression.
  • The Greatwall-endosulfine complex plays a role in mediating CDK1 activation following mTOR inhibition.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K